Lura Health — Implementation Playbook (DSO)

Lura Health Continuous Salivary Monitoring Implementation Playbook

A Strategic Guide for DSO Operators

Prepared for: VPs of Clinical Affairs, Chief Dental Officers, Strategy and Innovation Leadership Organization Type: Dental Service Organizations (5–50 Locations) Tool Category: Salivary Diagnostics / Biosensor Technology Version: 1.0 | Publication Date: 2026

1. Executive Summary

What Lura Health Does

Lura Health is a biosensor platform designed for continuous salivary monitoring using intraoral devices that measure biomarkers — including glucose, uric acid, and nitrite — in real time. The platform is positioned at the intersection of dentistry and systemic health, with a thesis that the oral environment can serve as a non-invasive, continuous window into metabolic and cardiovascular health markers.

For DSOs, Lura Health is a strategic technology question, not an operational one. The platform is in early commercial or research-partnership stages as of 2026. DSOs evaluating it should do so through the lens of clinical innovation investment, physician network integration strategy, and longer-term positioning in value-based care models — not near-term revenue generation or operational rollout.

The case for DSO engagement is distinct from solo practice engagement. A DSO operating 20+ locations has the patient volume to generate meaningful clinical data, the infrastructure to run standardized protocols across sites, and the organizational weight to negotiate research or early-access partnerships that a solo practice cannot. If salivary diagnostics becomes a reimbursed clinical service category, DSOs that have built operational protocols and clinical evidence in the early period will have a structural advantage.

Why DSOs Are the Right Early Adopter

Expected Timeline for DSO Strategic Engagement

• Month 1–3: Vendor diligence, regulatory review, research literature assessment
• Month 3–6: Define partnership structure (research collaboration, clinical trial, pilot program)
• Month 6–12: Pilot deployment at 2–5 locations under defined clinical protocol
• Year 2+: Evaluate expansion based on clinical outcomes and reimbursement landscape development

2. Pre-Implementation Checklist

• ☐ FDA regulatory status review: Engage regulatory counsel to review the device's clearance status, any 510(k) or de novo submissions, and the scope of cleared diagnostic claims — this is non-negotiable before patient use at scale
• ☐ IRB and research framework: If Lura Health is operating in a research context, determine whether DSO participation requires IRB review — multi-site research typically does
• ☐ Clinical affairs leadership review: Chief Dental Officer or VP of Clinical Affairs must sign off on the clinical protocol before any patient engagement; this is a clinical decision, not an operations decision
• ☐ Legal review of partnership structure: Research partnership vs. commercial licensing vs. pilot program — each has different IP, liability, and data ownership implications
• ☐ Informed consent framework: Develop a standardized informed consent document for all participating locations; not a per-location decision
• ☐ Physician referral infrastructure: Map existing physician referral relationships across your portfolio; salivary biomarker findings require a clear referral pathway or they are clinically incomplete
• ☐ Data governance policy: Biosensor data is PHI; define data handling, storage, access, and secondary use policies before deployment
• ☐ Staff training requirements: Determine what clinical training is needed at each location and whether that is scalable across your portfolio
• ☐ Reimbursement landscape assessment: Engage your payer relations team to assess any current or pipeline coverage for salivary diagnostic services
• ☐ Exit criteria: Define in advance what clinical or commercial milestones would lead to expanding, pausing, or terminating engagement

3. Implementation Phases

Phase 1: Strategic and Regulatory Foundation (Months 1–3)

Before any patient engagement, establish a clear organizational position: Is this a research partnership, a clinical innovation pilot, or an early commercial adoption? Each has different governance requirements, and conflating them creates regulatory and liability exposure.

Commission a regulatory memo from dental health law counsel covering: FDA clearance scope, state-level regulations on salivary diagnostic devices, and HIPAA implications of biosensor data flow. This document should exist before any location engages patients.

Simultaneously, develop the clinical protocol framework with your Chief Dental Officer: patient eligibility criteria, monitoring duration, data collection standards, result communication to patients, and physician referral triggers. The protocol must be standardized before rollout.

Phase 2: Structured Pilot Deployment (Months 3–6)

Select 2–5 pilot locations based on:

• Clinical leadership engagement (do the lead dentists understand and want to participate?)
• Patient demographics (meaningful proportion of patients with metabolic risk factors — diabetic, pre-diabetic, cardiovascular risk)
• Physician referral network access (are there local physicians to refer to when biomarker signals are flagged?)

Deploy the standardized clinical protocol, train location clinical teams, and establish data collection from day one. Treat this as a clinical study, not a commercial launch: document everything, track adverse events, and maintain research-grade records.

Phase 3: Evaluation and Decision (Month 6–12)

At the end of the pilot period, conduct a structured review:

• What biomarker signals were observed, and how did they correlate with known patient health status?
• What percentage of flagged patients were successfully referred to a physician?
• What was the patient acceptance rate for the monitoring device?
• What did clinical staff find manageable vs. burdensome?
• Has the reimbursement landscape shifted in any direction?

This review drives the expand/pause/exit decision. It should be presented to DSO leadership with a clear-eyed recommendation — not a momentum-driven default to expansion.

4. Integration Considerations

DSO-scale deployment of salivary monitoring requires solving integration problems that don't yet have standard answers:

• Patient record integration: How does biosensor data enter the patient chart? No major PMS has native salivary biomarker fields. Interim solutions likely involve PDF exports and manual notation.
• Centralized data aggregation: For the clinical data to be meaningful at the portfolio level, it must be aggregated. This requires a data pipeline from Lura Health's platform to a DSO data warehouse — verify API availability and data export formats.
• Physician communication: When a biomarker signal is flagged, what does the communication to the patient's primary care physician look like? Develop a standardized report format before any referrals are made.
• Infection control standardization: Device sterilization or single-use protocols must be standardized across all participating locations — not improvised per location.

5. Pricing and ROI Framework

Commercial pricing for Lura Health at DSO scale is not publicly established as of 2026. Early-stage partnerships may involve data contribution in exchange for device access, cost-sharing arrangements, or research grant structures.

For DSO financial modeling:

The honest financial picture for DSOs in 2026: this is an innovation investment with an uncertain return timeline, not a revenue line item. Budget it accordingly — as R&D, not operations.

6. Key Questions to Ask the Vendor

1. What is the precise FDA clearance status of the device, and what diagnostic or monitoring claims are cleared?
2. Are you seeking DSO partners for a research collaboration, a commercial pilot, or both — and what are the specific obligations and benefits of each?
3. What peer-reviewed published evidence exists for your biomarker accuracy claims?
4. Who owns the clinical data generated at DSO locations — and what secondary use rights does Lura Health retain?
5. What does a standardized clinical protocol for a multi-location DSO look like, and have you deployed one before?
6. What is the infection control requirement for the biosensor device?
7. Have you engaged any payers about potential reimbursement pathways, and what was the response?
8. What is your regulatory roadmap — what additional FDA submissions are planned, and on what timeline?
9. Who are your key clinical advisors and academic partners?

7. Red Flags and Considerations

• Regulatory status ambiguity: If the device's FDA clearance is unclear or limited, DSO deployment creates regulatory exposure across every participating location — a compounded risk vs. a single practice
• No peer-reviewed validation: Clinical data supporting the accuracy of salivary biomarker measurements for the claimed health signals must exist in peer-reviewed literature; marketing claims without published evidence are not sufficient for DSO clinical adoption
• Data ownership risks: Biosensor data from your patient population has significant potential value; ensure DSO data ownership and use restrictions are explicit in any partnership agreement
• Clinical staff burden at scale: If the protocol is burdensome for clinical staff, adoption will drop off quickly. Multi-location protocols that depend on high staff engagement without strong training infrastructure tend to decay within 6 months
• Physician referral infrastructure gap: Flagging a metabolic signal without a clear pathway for the patient to receive follow-up care is a patient safety concern. This infrastructure must exist before patient engagement
• No reimbursement path near-term: Building operational infrastructure around a service category with no current reimbursement is a bet on future market development — model for a 3–5 year horizon before financial return

8. Avized Verdict

Lura Health represents a scientifically grounded but commercially early concept. The oral-systemic biomarker thesis is supported by legitimate research, and the DSO context — with its volume, standardization capability, and organizational weight — is genuinely the right setting for structured early engagement. That said, as of 2026 this is a research bet, not a commercial decision.

DSOs best positioned to engage are those with a clinical innovation function, a Chief Dental Officer who is actively interested in oral-systemic integration, and existing physician referral network relationships. For everyone else, the appropriate posture is to monitor closely and revisit when the regulatory pathway is clearer and peer-reviewed evidence is more extensive.